Cargando…

Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation

BACKGROUND: The aim of this study was to evaluate apoptotic (Bcl-2, Bax expression, caspase-3 activity, and cytochrome-c) and angiogenic (MMP-9 levels and VEGF expression) markers in operable rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT) followed by total mesorect...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurt, Atilla, Yanar, Fatih, Asoglu, Oktar, Balik, Emre, Olgac, Vakur, Karanlik, Hasan, Kucuk, Sevda Tanrikulu, Ademoglu, Evin, Yegen, Gulcin, Bugra, Dursun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542157/
https://www.ncbi.nlm.nih.gov/pubmed/23276144
http://dx.doi.org/10.1186/1472-6890-12-27
_version_ 1782255463035830272
author Kurt, Atilla
Yanar, Fatih
Asoglu, Oktar
Balik, Emre
Olgac, Vakur
Karanlik, Hasan
Kucuk, Sevda Tanrikulu
Ademoglu, Evin
Yegen, Gulcin
Bugra, Dursun
author_facet Kurt, Atilla
Yanar, Fatih
Asoglu, Oktar
Balik, Emre
Olgac, Vakur
Karanlik, Hasan
Kucuk, Sevda Tanrikulu
Ademoglu, Evin
Yegen, Gulcin
Bugra, Dursun
author_sort Kurt, Atilla
collection PubMed
description BACKGROUND: The aim of this study was to evaluate apoptotic (Bcl-2, Bax expression, caspase-3 activity, and cytochrome-c) and angiogenic (MMP-9 levels and VEGF expression) markers in operable rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Understanding these factors will facilitate the identification of potential pathological responders before treatment, leading to better local control and survival rates. METHODS: Between March 2006 and March 2008, 29 patients withTNM Stage III (cT3 N+) mid or low rectal cancer were included in this study. Our sample consisted of 17 males (58.6%) and 12 females (41.4%). The median age was 60 years (range 24-88 years). Biopsy samples were taken from different portions of the tumors using flexible endoscopy before neoadjuvant CRT. Preoperatively, all patients received radiation (45-50.4 gray (Gy) in 25 cycles with concurrent 5-florouracil (5-FU) chemotherapy. RESULTS: A complete response was observed in 7 of 29 patients (24%). Bax staining was negative in 1 of the 7 patients (14%) in the pathological complete response (PCR) group and in 18 of the 22 patients (82%) in the no pathological complete response (noPCR) group (p = 0.001). MMP-9 and VEGF levels were higher in the noPCR group than the PCR group (p = 0.04, p = 0.05 respectively). No statistically significant differences were found between VEGF and MMP-9 levels in nodal downstaging. No statistically significant relationships were found between the other apoptotic factors (Bcl 2, cytochrome-c, and caspase-3 activity) and pathological response rate (p > 0.05). CONCLUSION: In neoadjuvant CRT patients, high levels of Bax expression and low levels of VEGF and MMP-9 expression on preoperative biopsies indicate that the patient will potentially be a good pathological responder.
format Online
Article
Text
id pubmed-3542157
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35421572013-01-11 Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation Kurt, Atilla Yanar, Fatih Asoglu, Oktar Balik, Emre Olgac, Vakur Karanlik, Hasan Kucuk, Sevda Tanrikulu Ademoglu, Evin Yegen, Gulcin Bugra, Dursun BMC Clin Pathol Research Article BACKGROUND: The aim of this study was to evaluate apoptotic (Bcl-2, Bax expression, caspase-3 activity, and cytochrome-c) and angiogenic (MMP-9 levels and VEGF expression) markers in operable rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Understanding these factors will facilitate the identification of potential pathological responders before treatment, leading to better local control and survival rates. METHODS: Between March 2006 and March 2008, 29 patients withTNM Stage III (cT3 N+) mid or low rectal cancer were included in this study. Our sample consisted of 17 males (58.6%) and 12 females (41.4%). The median age was 60 years (range 24-88 years). Biopsy samples were taken from different portions of the tumors using flexible endoscopy before neoadjuvant CRT. Preoperatively, all patients received radiation (45-50.4 gray (Gy) in 25 cycles with concurrent 5-florouracil (5-FU) chemotherapy. RESULTS: A complete response was observed in 7 of 29 patients (24%). Bax staining was negative in 1 of the 7 patients (14%) in the pathological complete response (PCR) group and in 18 of the 22 patients (82%) in the no pathological complete response (noPCR) group (p = 0.001). MMP-9 and VEGF levels were higher in the noPCR group than the PCR group (p = 0.04, p = 0.05 respectively). No statistically significant differences were found between VEGF and MMP-9 levels in nodal downstaging. No statistically significant relationships were found between the other apoptotic factors (Bcl 2, cytochrome-c, and caspase-3 activity) and pathological response rate (p > 0.05). CONCLUSION: In neoadjuvant CRT patients, high levels of Bax expression and low levels of VEGF and MMP-9 expression on preoperative biopsies indicate that the patient will potentially be a good pathological responder. BioMed Central 2012-12-31 /pmc/articles/PMC3542157/ /pubmed/23276144 http://dx.doi.org/10.1186/1472-6890-12-27 Text en Copyright ©2012 Kurt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kurt, Atilla
Yanar, Fatih
Asoglu, Oktar
Balik, Emre
Olgac, Vakur
Karanlik, Hasan
Kucuk, Sevda Tanrikulu
Ademoglu, Evin
Yegen, Gulcin
Bugra, Dursun
Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title_full Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title_fullStr Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title_full_unstemmed Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title_short Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
title_sort low mmp 9 and vegf levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3542157/
https://www.ncbi.nlm.nih.gov/pubmed/23276144
http://dx.doi.org/10.1186/1472-6890-12-27
work_keys_str_mv AT kurtatilla lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT yanarfatih lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT asogluoktar lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT balikemre lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT olgacvakur lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT karanlikhasan lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT kucuksevdatanrikulu lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT ademogluevin lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT yegengulcin lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation
AT bugradursun lowmmp9andvegflevelspredictgoodoncologicoutcomeinmidandlowrectalcancerpatientswithneoadjuvantchemoradiation